 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12345678910111213» |
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Enrollment closed: Iloprost in Preventing Lung Cancer in Former Smokers (clinicaltrials.gov) - Dec 4, 2019
P1, N=51, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Enrollment open: COMBAT-SHINE: Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in Patients With Septic Shock Suffering From Organ Failure (clinicaltrials.gov) - Nov 5, 2019
P2/3, N=380, Recruiting, Sponsor: Jakob Stensballe, MD, PhD
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
New P2/3 trial: COMBAT-SHINE: Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in Patients With Septic Shock Suffering From Organ Failure (clinicaltrials.gov) - Oct 11, 2019
P2/3, N=380, Not yet recruiting, Sponsor: Jakob Stensballe, MD, PhD
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion date, Trial primary completion date: ILO-HOPE: Inhaled Iloprost and Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction (clinicaltrials.gov) - Aug 14, 2019
P4, N=34, Recruiting, Sponsor: National Taiwan University Hospital
Not yet recruiting --> Recruiting Trial completion date: Sep 2018 --> Jan 2020 | Trial primary completion date: Sep 2018 --> Jan 2020
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Enrollment open: ThIlo: Iloprost in Acute Respiratory Distress Syndrome (clinicaltrials.gov) - Aug 8, 2019
P3, N=150, Recruiting, Sponsor: University Hospital Tuebingen
Trial completion date: Sep 2018 --> Jan 2020 | Trial primary completion date: Sep 2018 --> Jan 2020 Not yet recruiting --> Recruiting
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Enrollment open: SHINE-TRAUMA: Infusion of Prostacyclin vs Placebo for 72-hours in Trauma Patients With Haemorrhagic Shock Suffering From Organ Failure (clinicaltrials.gov) - May 23, 2019
P2, N=220, Recruiting, Sponsor: P
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
New trial, Surgery: The Effect of Iloprost on Oxygenation During One-lung Ventilation for Lung Surgery (clinicaltrials.gov) - May 2, 2019
P=N/A, N=72, Completed, Sponsor: Seoul St. Mary's Hospital
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion date, Trial primary completion date: ThIlo: Iloprost in Acute Respiratory Distress Syndrome (clinicaltrials.gov) - Apr 19, 2019
P3, N=150, Not yet recruiting, Sponsor: University Hospital Tuebingen
Not yet recruiting --> Recruiting Trial completion date: Sep 2021 --> Jan 2022 | Trial primary completion date: Jun 2021 --> Oct 2021
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
New P2 trial: SHINE-TRAUMA: Infusion of Prostacyclin vs Placebo for 72-hours in Trauma Patients With Haemorrhagic Shock Suffering From Organ Failure (clinicaltrials.gov) - Apr 3, 2019
P2, N=220, Not yet recruiting, Sponsor: P
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial primary completion date: Iloprost in Preventing Lung Cancer in Former Smokers (clinicaltrials.gov) - Mar 13, 2019
P1, N=50, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Sep 2021 --> Jan 2022 | Trial primary completion date: Jun 2021 --> Oct 2021 Trial primary completion date: Feb 2019 --> Feb 2020
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial initiation date, Trial primary completion date: ILOPROST in Septic Shock With Persistent Microperfusion Defects (I-MICRO) (clinicaltrials.gov) - Mar 13, 2019
P3, N=236, Not yet recruiting, Sponsor: Assistance Publique - H
Trial primary completion date: Feb 2019 --> Feb 2020 Initiation date: Jan 2019 --> Apr 2019 | Trial primary completion date: Jan 2021 --> Apr 2021
- || Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Enrollment change, Metastases: VENTASTEP: Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension (clinicaltrials.gov) - Mar 1, 2019
P=N/A, N=50, Recruiting, Sponsor: Bayer
Initiation date: Jan 2019 --> Apr 2019 | Trial primary completion date: Jan 2021 --> Apr 2021 N=100 --> 50
- || Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion date, Trial primary completion date, Metastases: VENTASTEP: Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension (clinicaltrials.gov) - Jan 23, 2019
P=N/A, N=100, Recruiting, Sponsor: Bayer
N=100 --> 50 Trial completion date: Jul 2019 --> Mar 2020 | Trial primary completion date: Jan 2019 --> Dec 2019
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
New P3 trial: ILOPROST in Septic Shock With Persistent Microperfusion Defects (I-MICRO) (clinicaltrials.gov) - Dec 28, 2018
P3, N=236, Not yet recruiting, Sponsor: Assistance Publique - H
- ||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion, Phase classification, Enrollment change, Trial completion date, Trial primary completion date: PILGRIM: Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Dec 27, 2018
P=N/A, N=73, Completed, Sponsor: Gachon University Gil Medical Center
Trial completion date: Jul 2019 --> Mar 2020 | Trial primary completion date: Jan 2019 --> Dec 2019 Recruiting --> Completed | Phase classification: P4 --> PN/A | N=48 --> 73 | Trial completion date: Dec 2016 --> Dec 2018 | Trial primary completion date: Jun 2016 --> Dec 2018
- Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion date, Trial primary completion date: OVATION: Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension (clinicaltrials.gov) - Dec 17, 2018
P4, N=50, Recruiting, Sponsor: Duke University
Recruiting --> Completed | Phase classification: P4 --> PN/A | N=48 --> 73 | Trial completion date: Dec 2016 --> Dec 2018 | Trial primary completion date: Jun 2016 --> Dec 2018 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2019
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion, Trial completion date: Acute Response of Iloprost Inhalation Using the Breelib Nebulizer in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Oct 26, 2018
P=N/A, N=30, Completed, Sponsor: University of Giessen
Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2019 Recruiting --> Completed | Trial completion date: Sep 2019 --> Oct 2018
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion date, Trial primary completion date: ILOFLOW: The Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation (clinicaltrials.gov) - Oct 17, 2018
P2, N=100, Recruiting, Sponsor: Prim PD Dr Afshin Assadian
Recruiting --> Completed | Trial completion date: Sep 2019 --> Oct 2018 Trial completion date: Jun 2018 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Jun 2019
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date: ThIlo: Iloprost in Acute Respiratory Distress Syndrome (clinicaltrials.gov) - Oct 16, 2018
P3, N=150, Not yet recruiting, Sponsor: University Hospital Tuebingen
Trial completion date: Jun 2018 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Jun 2019 N=900 --> 150 | Trial completion date: Jan 2021 --> Sep 2021 | Initiation date: Jun 2018 --> Jan 2019 | Trial primary completion date: Oct 2020 --> Jun 2021
- ||| Trial completion: PAH QuERI Ext: Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program (clinicaltrials.gov) - Aug 15, 2018
P=N/A, N=797, Completed, Sponsor: Actelion
N=900 --> 150 | Trial completion date: Jan 2021 --> Sep 2021 | Initiation date: Jun 2018 --> Jan 2019 | Trial primary completion date: Oct 2020 --> Jun 2021 Active, not recruiting --> Completed
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
New P4 trial: ILO-HOPE: Inhaled Iloprost and Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction (clinicaltrials.gov) - Aug 8, 2018
P4, N=34, Recruiting, Sponsor: National Taiwan University Hospital
- ||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion: OPTION: Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years (clinicaltrials.gov) - Jul 18, 2018
P=N/A, N=118, Completed, Sponsor: Bayer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial primary completion date: Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Jul 9, 2018
P=N/A, N=270, Recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Trial primary completion date: Sep 2022 --> Mar 2022
- || Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Enrollment change, Compliance: IVENT: Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension (clinicaltrials.gov) - Jul 2, 2018
P=N/A, N=89, Completed, Sponsor: Bayer
Trial primary completion date: Sep 2022 --> Mar 2022 N=59 --> 89
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion: Effect of Iloprost on Pulmonary Oxygenation in Patients With Low Diffusing Capacity During One-lung Ventilation (clinicaltrials.gov) - Jun 20, 2018
P=N/A, N=40, Completed, Sponsor: Yonsei University
N=59 --> 89 Recruiting --> Completed
- || Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Phase classification, Compliance: Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation (clinicaltrials.gov) - Apr 9, 2018
P, N=13, Completed, Sponsor: Bayer
Recruiting --> Completed Phase classification: P=N/A --> P
- || Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Phase classification, Metastases: VENTASTEP: Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension (clinicaltrials.gov) - Apr 4, 2018
P, N=100, Recruiting, Sponsor: Bayer
Phase classification: P=N/A --> P Phase classification: P=N/A --> P
- ||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion, Compliance: IVENT: Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension (clinicaltrials.gov) - Mar 15, 2018
P=N/A, N=59, Completed, Sponsor: Bayer
Phase classification: P=N/A --> P Active, not recruiting --> Completed
- || Trial completion date, Trial primary completion date: PAH QuERI Ext: Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program (clinicaltrials.gov) - Mar 12, 2018
P=N/A, N=797, Active, not recruiting, Sponsor: Actelion
Active, not recruiting --> Completed Trial completion date: Mar 2018 --> Jun 2018 | Trial primary completion date: Jan 2018 --> Jun 2018
- || Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion date, Trial primary completion date: OPTION: Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years (clinicaltrials.gov) - Mar 7, 2018
P=N/A, N=118, Active, not recruiting, Sponsor: Bayer
Trial completion date: Mar 2018 --> Jun 2018 | Trial primary completion date: Jan 2018 --> Jun 2018 Trial completion date: Feb 2018 --> Mar 2018 | Trial primary completion date: Feb 2018 --> Mar 2018
- ||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Metastases: VENTASTEP: Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension (clinicaltrials.gov) - Mar 6, 2018
P=N/A, N=100, Recruiting, Sponsor: Bayer
Trial completion date: Feb 2018 --> Mar 2018 | Trial primary completion date: Feb 2018 --> Mar 2018 Not yet recruiting --> Recruiting | Trial completion date: Mar 2019 --> Jul 2019 | Initiation date: Jan 2018 --> Feb 2018 | Trial primary completion date: Jan 2019 --> Jan 2019
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion date, Compliance: IVENT: Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension (clinicaltrials.gov) - Mar 3, 2018
P=N/A, N=59, Active, not recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting | Trial completion date: Mar 2019 --> Jul 2019 | Initiation date: Jan 2018 --> Feb 2018 | Trial primary completion date: Jan 2019 --> Jan 2019 Trial completion date: Feb 2018 --> Feb 2018
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
New P4 trial: ND ND (EUDRACT) - Feb 27, 2018
P4, N=238, Ongoing, Sponsor: UNIVERSIT
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion date, Trial primary completion date: ILOFLOW: The Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation (clinicaltrials.gov) - Feb 15, 2018
P2, N=100, Recruiting, Sponsor: Prim PD Dr Afshin Assadian
Trial completion date: Feb 2018 --> Feb 2018 Trial primary completion date: Oct 2016 --> Jun 2018 | Trial completion date: Oct 2016 --> Jun 2018
- || Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial primary completion date: OPTION: Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years (clinicaltrials.gov) - Jan 31, 2018
P=N/A, N=118, Active, not recruiting, Sponsor: Bayer
Trial primary completion date: Oct 2016 --> Jun 2018 | Trial completion date: Oct 2016 --> Jun 2018 Trial primary completion date: Nov 2017 --> Feb 2018
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
New trial: ADUL-SSc: Autologous Adipose Tissue in the Treatment of Systemic Sclerosis Digital Ulcers (clinicaltrials.gov) - Jan 23, 2018
P=N/A, N=46, Recruiting, Sponsor: ASST Gaetano Pini-CTO
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
New trial: The Effect of Iloprost on Capillary Recruitment and Insulin Sensitivity in Type 2 Diabetes (clinicaltrials.gov) - Dec 21, 2017
P=N/A, N=15, Completed, Sponsor: VU University Medical Center
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
New trial: Acute Response of Iloprost Inhalation Using the Breelib Nebulizer in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Dec 7, 2017
P=N/A, N=30, Recruiting, Sponsor: University of Giessen
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion: Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease (clinicaltrials.gov) - Nov 29, 2017
P2, N=152, Completed, Sponsor: University of Colorado, Denver
Trial primary completion date: Nov 2017 --> Feb 2018 Recruiting --> Completed
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion: ENDO-RCA: Endothelial Dysfunction in Resuscitated Cardiac Arrest (clinicaltrials.gov) - Nov 24, 2017
P2, N=50, Completed, Sponsor: P
Recruiting --> Completed Active, not recruiting --> Completed
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion: Comparative PK PD Study in PAH Patients (Fox vs. I-Neb) (clinicaltrials.gov) - Oct 23, 2017
P1/2, N=27, Completed, Sponsor: Bayer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial primary completion date: Iloprost in Preventing Lung Cancer in Former Smokers (clinicaltrials.gov) - Oct 12, 2017
P1, N=61, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Oct 2018 --> Feb 2019
- ||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
New trial, Metastases: VENTASTEP: Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension (clinicaltrials.gov) - Sep 26, 2017
P=N/A, N=100, Not yet recruiting, Sponsor: Bayer
- || Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Enrollment closed, Enrollment change, Compliance: IVENT: Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension (clinicaltrials.gov) - Sep 25, 2017
P=N/A, N=59, Active, not recruiting, Sponsor: Bayer
Trial primary completion date: Oct 2018 --> Feb 2019 Recruiting --> Active, not recruiting | N=100 --> 59
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Phase classification: SPHERA: Efficacy of Ventavis Used in Real-life Setting. (clinicaltrials.gov) - Sep 21, 2017
P=N/A, N=52, Completed, Sponsor: Bayer
Recruiting --> Active, not recruiting | N=100 --> 59 Phase classification: P4 --> P=N/A
- || Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial primary completion date: OPTION: Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years (clinicaltrials.gov) - Aug 15, 2017
P=N/A, N=118, Active, not recruiting, Sponsor: Bayer
Phase classification: P4 --> P=N/A Trial primary completion date: Jun 2017 --> Sep 2017
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Enrollment open: OVATION: Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension (clinicaltrials.gov) - Jul 24, 2017
P4, N=50, Recruiting, Sponsor: Duke University
Trial primary completion date: Jun 2017 --> Sep 2017 Not yet recruiting --> Recruiting
- Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial primary completion date: OVATION: Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension (clinicaltrials.gov) - Jun 2, 2017
P4, N=50, Not yet recruiting, Sponsor: Duke University
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2018 --> Dec 2018
- || Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial primary completion date: OPTION: Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years (clinicaltrials.gov) - May 8, 2017
P=N/A, N=118, Active, not recruiting, Sponsor: Bayer
Trial primary completion date: Jul 2018 --> Dec 2018 Trial primary completion date: Feb 2017 --> Jun 2017
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion, Compliance: Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation (clinicaltrials.gov) - May 3, 2017
P=N/A, N=13, Completed, Sponsor: Bayer
Trial primary completion date: Feb 2017 --> Jun 2017 Active, not recruiting --> Completed